| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | Chief Business Officer
2 companies
Jeremy P. Springhorn is Director at QURE and has filed Form 4s across 2 companies. Jeremy P. Springhorn's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $1.0M at current prices.
Historically, Jeremy P. Springhorn's trades have earned a below-average insider score of 46/100 across 6 rated trades. Over a 12-month horizon, 40.0% of those trades were profitable, with an average 12-month return of -16.1%.
The biggest single holding is QURE (~$1.0M) as Director. The QURE filings lean toward selling, a net 12,130 shares.
Jeremy P. Springhorn has 24 Form 4 filings on record from September 2017 to June 2026, across 2 companies: Director at uniQure (QURE), 2017–2026; Chief Business Officer at Syros Pharmaceuticals (SYRS), 2017–2021.
The 40 reported transactions were 16 option or other derivative awards, 11 stock awards, 10 open-market sales and 3 open-market purchases.
Counted by filing, the open-market trades come to 2 purchases worth about $236K and 9 sales worth about $264K.
The largest open-market purchase was 15,000 shares of SYRS at an average $9.08 on December 15, 2017, about $136K.
The largest open-market sale was 1,993 shares of QURE at an average $27.06 on June 11, 2026, about $54K.
None of the 4 sales since April 2023 was marked as made under a Rule 10b5-1 trading plan.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 11, 2026 | QURE Uniqure N.V. | Director | Sell | 1,993 | $27.06 | $53,930.58 | -4.4% | +71.5% | - | |
| Jun 20, 2025 | QURE Uniqure N.V. | Director | Sell | 2,112 | $14.45 | $30,518.40 | -5.3% | +3.7% | +212.4% | |
| Jun 13, 2024 | QURE Uniqure N.V. | Director | Sell | 2,231 | $5.12 | $11,422.72 | -8.6% | +4.2% | +192.2% | |
| Jun 16, 2023 | QURE Uniqure N.V. | Director | Sell | 2,286 | $18.88 | $43,159.68 | -8.1% | -60.6% | -74.9% | |
| Feb 27, 2023 | QURE Uniqure N.V. | Director | Sell | 384 | $20.41 | $7,837.44 | -1.9% | -8.4% | -67.9% | |
| Feb 28, 2022 | QURE Uniqure N.V. | Director | Sell | 602 | $16.70 | $10,053.40 | -5.2% | -15.5% | +23.4% | |
| Mar 2, 2021 | QURE Uniqure N.V. | Director | Sell | 505 | $37.50 | $18,937.50 | -4.8% | - | - | |
| Jan 28, 2020 | QURE Uniqure N.V. | Director | Sell | 807 | $62.19 | $50,190.36 | -11.8% | - | - | |
| Nov 12, 2019 | SYRS Syros Pharmaceuticals, Inc. | Chief Business Officer | Buy | 20,000 | $4.98 | $99,595.79 | +133.3% | - | - | |
| Jan 28, 2019 | QURE Uniqure N.V. | Director | Sell | 1,210 | $31.32 | $37,897.20 | -15.1% | - | - |